|
Implant Sciences QS-B220 Trace Detection System Gains Further Traction in the European Airport Security Market
WILMINGTON, MA, Dec 10, 2012 (MARKETWIRE via COMTEX) --
Implant Sciences Corporation (OTCQB: IMSC), a high technology
supplier of systems and sensors for homeland security and defense
markets, today announced that it has sold its Quantum Sniffer(TM)
QS-B220 desktop explosives and drugs trace detector to a new customer
in Europe. The unit will be used for airport security at a major
international airport in Europe.
"Designed to meet the requirements of aviation security
professionals, our desktop trace detector is gaining increasing
acceptance and traction in global markets. As we continue to grow our
distribution channel, we look forward to demonstrating its advantages
in increasing numbers of procurements," stated Implant Sciences'
President and CEO, Glenn D. Bolduc.
"The QS-B220 provides an effective method for screening passengers
without concerns about radiation and privacy. This and the ability to
adapt the easy-to-use touch-screen interface to the local language
were important factors in Implant Sciences winning this order from a
new customer through a new distributor," added Dr. Darryl Jones,
Implant Sciences' Vice President of Sales and Marketing.
About the Quantum Sniffer(TM) QS-B220 Desktop Explosives Trace
Detector
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to
rapidly detect and identify trace amounts of a wide variety of
military, commercial, and homemade explosives, as well as drugs.
Featuring a radioactive material-free design, push-button maintenance
and diagnostics, and internal automatic self-calibration, the QS-B220
brings new levels of performance and convenience to desktop trace
detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated
sensors and systems for Security, Safety, and Defense (SS&D) markets.
The Company has developed proprietary technologies used in its
commercial explosive and narcotics trace detection systems which ship
to a growing number of locations domestically and internationally.
Implant Sciences' QS-H150 portable explosives trace detector has
received Qualified Anti-Terrorism Technology Designation and the
Company's QS-B220 desktop explosives and drugs trace detector has
received a Developmental Testing & Evaluation (DT&E) Designation by
the U.S. Department of Homeland Security under the Support
Anti-terrorism by Fostering Effective Technology Act of 2002 (the
SAFETY Act). For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements,"
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Such statements are based on management's current
expectations and are subject to risks and uncertainties that could
cause the Company's actual results to differ materially from the
forward-looking statements. Such risks and uncertainties include, but
are not limited to, the risks that our explosives detection products
and technologies (including any new products we may develop) may not
be accepted by the Transportation Security Administration or by other
U.S. or foreign government and law enforcement agencies or commercial
consumers of security products; economic, political and other risks
associated with international sales and operations could adversely
affect our sales; our business is subject to intense competition and
rapid technological change; the risks that our markets are subject to
technological change and that our success depends on our ability to
develop and introduce new products; and other risks and uncertainties
described in our filings with the Securities and Exchange Commission,
including its most recent Forms 10-K, 10-Q and 8-K. Such statements
are based on management's current expectations and assumptions which
could differ materially from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
SOURCE: Implant Sciences Corporation
http://www2.marketwire.com/mw/emailprcntct id=89BDCA2DAEAEB9B5
http://www2.marketwire.com/mw/emailprcntct id=D5698B1044601E0C
[ InfoTech Spotlight's Homepage ]
|
